International development and implementation of a core measurement set for research and audit studies in implant-based breast reconstruction: a study protocol.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
20 01 2020
Historique:
entrez: 23 1 2020
pubmed: 23 1 2020
medline: 11 2 2021
Statut: epublish

Résumé

Outcome reporting in research studies of breast reconstruction is inconsistent and lacks standardisation. The results of individual studies therefore cannot be meaningfully compared or combined limiting their value. A core outcome set (COS) has been developed to address these issues and identified 11 key outcomes to be measured and reported in all future research and audit studies in reconstructive breast surgery (RBS). A COS represents what key outcomes should be measured. The next step is to determine how and when this should be done. The aim of this study is to develop a core measurement set (CMS) for use in research and audit studies in implant-based breast reconstruction. The CMS will be developed in accordance with the guidance developed by the Core Outcome Measures in Effectiveness Trials initiative (COMET) and COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) group for the selection of outcome measurement instruments (OMIs) for relevant outcome domains included in the RBS COS. This will involve three phases with strategies to promote implementation as a final additional phase. The phases are (1) conceptual considerations in which the target population, procedures and settings are defined; (2) systematic reviews to identify existing clinical, patient-reported and cosmetic OMIs and, if appropriate, assess their quality using COSMIN methodology; (3) a modified Delphi process including sequential Delphi surveys involving approximately 100 healthcare professionals and a face to face consensus meeting to agree and ratify which outcome definitions and OMIs should be used and standardised time points for assessment; (4) strategies to promote dissemination and adoption of the CMS. Ethical approval has been granted by University of Bristol Faculty Research Ethics Committee FREC ID 60221. Dissemination strategies will include scientific meeting presentations and peer-reviewed journal publications. Implementation activities will include engagement with journal editors and funders to promote uptake and use of the CMS.

Identifiants

pubmed: 31964677
pii: bmjopen-2019-035505
doi: 10.1136/bmjopen-2019-035505
pmc: PMC7045234
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e035505

Subventions

Organisme : Department of Health
ID : CS-2016-16-019
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom
Organisme : Department of Health
ID : PB-PG-0214-33065
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Clin Rheumatol. 2014 Sep;33(9):1313-22
pubmed: 24970597
Qual Life Res. 2010 May;19(4):539-49
pubmed: 20169472
PLoS Med. 2011 Jan 25;8(1):e1000393
pubmed: 21283604
J Clin Epidemiol. 2014 Jul;67(7):745-53
pubmed: 24582946
Br J Surg. 2015 Oct;102(11):1360-71
pubmed: 26179938
J Natl Cancer Inst. 2011 Jan 5;103(1):31-46
pubmed: 21131574
Qual Life Res. 2012 May;21(4):651-7
pubmed: 21732199
Trials. 2013 Oct 09;14:324
pubmed: 24103529
Eur J Surg Oncol. 2017 Jan;43(1):52-61
pubmed: 27776942
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
J Invest Dermatol. 2015 Jan;135(1):24-30
pubmed: 25186228
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Trials. 2012 Aug 06;13:132
pubmed: 22867278
J Clin Epidemiol. 2011 Apr;64(4):395-400
pubmed: 21194891
Trials. 2016 Sep 13;17(1):449
pubmed: 27618914
Qual Life Res. 2009 Oct;18(8):1115-23
pubmed: 19711195
Trials. 2014 Jun 25;15:247
pubmed: 24962012
BMC Med Res Methodol. 2010 Mar 18;10:22
pubmed: 20298572
Plast Reconstr Surg. 2013 Jan;131(1):15-23
pubmed: 23271515
J Clin Epidemiol. 2014 Apr;67(4):401-9
pubmed: 24581294
BMJ. 2018 Jul 6;362:k2607
pubmed: 29980528
Trials. 2016 Mar 10;17(1):131
pubmed: 26965046
Trials. 2016 Sep 23;17(1):463
pubmed: 27664072
Lancet Oncol. 2018 Oct;19(10):e521-e533
pubmed: 30303126

Auteurs

Shelley Potter (S)

Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical School, Canynge Hall, Bristol, UK shelley.potter@bristol.ac.uk.
Bristol Breast Care Centre, Southmead Hospital, Bristol, UK.

Charlotte Davies (C)

Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical School, Canynge Hall, Bristol, UK.

Christopher Holcombe (C)

Linda McCartney Centre, Royal Liverpool and Broadgreen University Hospital, Liverpool, UK.

Eva Weiler-Mithoff (E)

Canniesburn Department of Plastic Surgery, Glasgow Royal Infirmary, Glasgow, UK.

Joanna Skillman (J)

Department of Plastic Surgery, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.

Raghavan Vidya (R)

New Cross Hospital, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK.

Yazan Masannat (Y)

Breast Unit, Aberdeen Royal Infirmary, Aberdeen, UK.

Walter Weber (W)

University Hospital and University of Basel, Basel, Switzerland.

Joerg Heil (J)

University Hospital Heidelberg, Heidelberg, Germany.

Sherif Wilson (S)

Bristol Breast Care Centre, Southmead Hospital, Bristol, UK.

Steven Thrush (S)

Breast Unit, Worcester Royal Hospital, Worcester, UK.

Lisa Whisker (L)

Nottingham University Hospitals NHS Trust, Nottingham, UK.

Jane Blazeby (J)

Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical School, Canynge Hall, Bristol, UK.

Chris Metcalfe (C)

Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical School, Canynge Hall, Bristol, UK.

Kerry Avery (K)

Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical School, Canynge Hall, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH